Patent · US Active

Anti-CD73 antibodies and uses thereof

US10584169B2 · kind B2 · utility

3Cited by

0References

14Claims

0Family size

Assignee

I-MAB BIOPHARMA US LIMITED · US

Inventors

Zhengyi Wang · Shanghai, CN
Lei Fang · Katy, US
Bingshi Guo · Shanghai, CN
Jingwu Zang · Shanghai, CN

Key dates

Filing date	Jan 23, 2018
Grant date	Mar 10, 2020
Priority date	—
Expiry date	Jan 23, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are anti-CD73 antibodies or fragments thereof. The antibodies or fragments therefore include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. More generally, antibodies or fragments thereof are described which have specificity to one or more amino acid residues selected from the C-terminal half of a human CD73 protein, such as those in the C-terminal domains. Specific epitope amino acids in these domains include Y345, D399, E400, R401 and R480. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.